Some genes are detected and considered as therapeutic potential targets in HF treatment, such as ANGPTL4 for HFpEF,[71] SPP1+ macrophages for AF treatment.[72] For example, cytokine Osm is expressed both in proinflammatory cytokine‐producing M1 subclusters and cardiac patient hearts, which may offer a novel explanation for the failure of anti‐tumor necrosis factor therapy trials in patients with HF. The gene discussed is ANGPTL4; the disease is hydrops fetalis.